Interés Humano

EE. UU. aprueba tercera dosis de vacuna contra covid-19 para mayores de 18 años

La autorización de uso de emergencia de la FDA fue concedida a los laboratorios Pfizer y Moderna

(FILES) In this file photo taken on March 04, 2021 shows vials of the Pfizer-BioNTech vaccine against COVID-19 amid the coronavirus pandemic in Panama City. - A booster shot of the anti-Covid-19 vaccine developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection, according to trial data published by the makers on October 21, 2021. The clinical phase three trial with "10,000 participants 16 years of age and older" showed "a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain", the companies said in a statement. (Photo by Luis ACOSTA / AFP)
(FILES) In this file photo taken on March 04, 2021 shows vials of the Pfizer-BioNTech vaccine against COVID-19 amid the coronavirus pandemic in Panama City. - A booster shot of the anti-Covid-19 vaccine developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection, according to trial data published by the makers on October 21, 2021. The clinical phase three trial with "10,000 participants 16 years of age and older" showed "a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain", the companies said in a statement. (Photo by Luis ACOSTA / AFP) LUIS ACOSTA
‌
‌

‌

‌
‌

‌

‌